---
schema_version: "secwatch.filing_event.v1"
accession: "0000917520-25-000069"
form_type: "8-K"
ticker: "IART"
cik: "0000917520"
company_name: "INTEGRA LIFESCIENCES HOLDINGS CORP"
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:40:25.169550+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Integra LifeSciences Q2 GAAP EPS –$6.31 on $511M goodwill impairment; adj EPS $0.45 vs $0.63 YoY

## Summary
- Revenue $415.6M, down 0.6% reported and 1.4% organic YoY; Codman Specialty Surgical flat, Tissue Tech down 4.1%.
- GAAP net loss $484.1M includes $511M goodwill impairment; adjusted EBITDA $71.2M (17.1% margin) vs $83.8M (20.0%) prior year.
- Full-year 2025 revenue guidance narrowed to $1.655B–$1.680B; adj EPS reaffirmed at $2.19–$2.29.
- Net debt $1.59B; total leverage ratio 4.5x; liquidity ~$1.14B including $254M cash and short-term investments.
- Completed all manufacturing site baseline assessments under Compliance Master Plan; no new shipping holds in Q2.

## SEC filing metadata
- accession: 0000917520-25-000069
- form_type: 8-K
- ticker: IART
- cik: 0000917520
- company_name: INTEGRA LIFESCIENCES HOLDINGS CORP
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/917520/000091752025000069/0000917520-25-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/917520/000091752025000069/iart-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000917520-25-000069
- JSON: https://secwatch.observer/filing/0000917520-25-000069.json
- Plain text: https://secwatch.observer/filing/0000917520-25-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.